Local Institution

London, Ontario N6H 0G6

0 studies enrolling now · 26 studies all time

What they study most

Acute Coronary Syndrome, Acute Coronary Syndrome (ACS), Acute Coronary Syndromes, Advanced Cutaneous Melanoma, Alzheimer's Disease, Atrial Fibrillation, Atrial Flutter, Bladder Cancer, Bladder Neoplasms, Cancer, Crohn's Disease, Diabetes Mellitus, Type 2

Studies at this site

• Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC — Completed
• An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3) — Completed
• Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma — Completed
• A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma — Completed
• Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia — Completed
• A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart — Completed
• Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes — Completed
• Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation — Completed
• First Line Hepato Cellular Carcinoma (HCC) — Completed
• Expanded Access Program With Nivolumab to Treat Melanoma — NO_LONGER_AVAILABLE
• A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer — Completed
• A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc) — Withdrawn before enrolling
• Phase III Acute Coronary Syndrome — Stopped early
• Safety Study of Apixaban in Recent Acute Coronary Syndrome — Completed
• First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy — Completed
• A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease — Stopped early
• Safety Study of BMS-823778 in Subjects With Hypercholesterolemia — Completed
• Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin — Completed
• Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone — Completed
• A Study of Abatacept in Patients With Active Ulcerative Colitis — Completed
• Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease — Completed
• Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension — Completed
• Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes — Completed
• Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone — Completed
• A Study of Abatacept in Patients With Active Crohn's Disease — Stopped early
• Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium — Completed